(NewsDirect)
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Lathamtells Proactive the company has appointed two highly experienced leadprincipal investigators for its Phase 2/3 clinical trial of IHL-42X, atreatment for obstructive sleep apnoea (OSA). The investigators, DrJohn D Hudson of FutureSearch Trials of Neurology in Austin, Texas,and Dr Russell Rosenberg of Neurotrials Research Inc in Atlanta,Georgia, will play a crucial role overseeing the first clinical trialsites, handling submissions to the FDA and obtaining ethics approvalfrom Institutional Review Boards.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
Jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.